Anti-Cd32B Monoclonal Antibody Bi-1206
B-Cell Chronic Lymphocytic Leukemia
Explore 67 assets in B-Cell Chronic Lymphocytic Leukemia →Floatz Rating
CCC50/100
Confidence
Indicative
Sponsor
Cancer Research UK
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02933320CT.gov BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · B-Cell Chronic Lymphocytic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Anti-Cd32B Monoclonal Antibody Bi-1206 (this asset) | Cancer Research UK | P1/2 | CCC · 50 |
| Humax-Cd20 | Emory University | P4 | BBB |
| Acalabrutinib | Zulfa Omer | P4 | BBB |
| Fludarabine | Ohio State University Comprehensive Cancer Center | P4 | BBB |
| Rituximab | Zulfa Omer | P4 | BBB |
| Cyclophosphamide | Ohio State University Comprehensive Cancer Center | P4 | BBB |
| Obinutuzumab | Paolo Caimi, MD | P3 | BB |
| Cediranib | City of Hope Medical Center | P2 | BB |
| Bendamustine | Mayo Clinic | P3 | BB |
+42 more in the B-Cell Chronic Lymphocytic Leukemia cohort
Other indications for Anti-Cd32B Monoclonal Antibody Bi-1206
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Waldenstrom Macroglobulinemia | — | P1/2 | CCC · 50 |
| Indolent B-Cell Non-Hodgkin Lymphoma | — | P1/2 | CC · 47 |
| B-Cell Non-Hodgkin Lymphoma | — | P1/2 | CC · 46 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Anti-Cd32B Monoclonal Antibody Bi-1206 in B-Cell Chronic Lymphocytic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/anti-cd32b-monoclonal-antibody-bi-1206-b-cell-chronic-lymphocytic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →